Berkshire Hathaway raised its stake in Teva during Q2
On August 14, Warren Buffett’s Berkshire Hathaway (BRKB) announced its holdings at the end of the second quarter. According to the company’s SEC filings, it held 43.2 million shares of Teva Pharmaceutical (TEVA) stock. It added 40.5 million shares during the first quarter, according to its filings on March 31.
Berkshire Hathaway added the stock to its portfolio in the fourth quarter of 2017 with 19.0 million Teva shares. At that time, TEVA stock was trading at record lows. On August 14, Teva stock was up ~1.2% in after-hours trading. Other major expanded investments by Berkshire Hathaway in the second quarter included Apple (AAPL) and Goldman Sachs (GS).
Recent Wall Street recommendations on Teva stock
On August 17, Teva Pharmaceutical Industries had a consensus analysts target price of $21.09, representing a 12-month return potential of -12.5%. However, ~56.0% of the 27 analysts surveyed by Reuters survey provided a “hold” recommendation on TEVA stock. Six of the analysts gave a “buy” rating on the stock, and the remaining seven analysts rated TEVA stock as a “buy.”
Teva stock has gained ~27.0% year-to-date on the back of the positive news that included product launches and study data. The company also remains on track with its restructuring initiatives. However, its earnings results have been a little disappointing.
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!